CALC Projected Dividend Yield
CalciMedica Inc ( NASDAQ : CALC )CalciMedica, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies that inhibit calcium release-activated calcium (CRAC) channels to treat acute and chronic inflammatory and immunologic diseases. Its lead candidate, Auxora, is a selective intravenous small molecule CRAC channel inhibitor containing zegocractin, which has shown promise in reducing cell injury and inflammation in organs like the pancreas, lungs, and kidneys in animal models. The company is currently conducting a Phase 2b trial (CARPO) for acute pancreatitis with systemic inflammatory response syndrome and supporting a Phase 1/2 study on asparaginase-induced pancreatic toxicity (CRSPA). 21 YEAR PERFORMANCE RESULTS |
CALC Dividend History Detail CALC Dividend News CALC Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |